Adaptimmune Therapeutics PLC (NASDAQ:ADAP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday. The firm currently has a $9.75 price target on the biotechnology company’s stock. Zacks Investment Research‘s price objective would suggest a potential upside of 14.30% from the stock’s current price.
According to Zacks, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. “
A number of other brokerages have also commented on ADAP. Cowen and Company restated a “buy” rating on shares of Adaptimmune Therapeutics PLC in a report on Tuesday, June 6th. BidaskClub upgraded shares of Adaptimmune Therapeutics PLC from a “sell” rating to a “hold” rating in a report on Sunday, July 16th. Leerink Swann restated an “outperform” rating and set a $15.00 price objective on shares of Adaptimmune Therapeutics PLC in a report on Friday, September 8th. Finally, ValuEngine upgraded shares of Adaptimmune Therapeutics PLC from a “strong sell” rating to a “sell” rating in a report on Thursday, July 20th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $12.38.
Shares of Adaptimmune Therapeutics PLC (ADAP) opened at 8.53 on Wednesday. The firm’s 50-day moving average is $8.47 and its 200 day moving average is $8.47. Adaptimmune Therapeutics PLC has a 52 week low of $3.76 and a 52 week high of $9.29.
Adaptimmune Therapeutics PLC (NASDAQ:ADAP) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.24) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.24). The company had revenue of $3.52 million for the quarter, compared to analysts’ expectations of $5.43 million. Adaptimmune Therapeutics PLC had a negative net margin of 438.00% and a negative return on equity of 38.73%. Equities research analysts anticipate that Adaptimmune Therapeutics PLC will post ($0.99) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Adaptimmune Therapeutics PLC (ADAP) Rating Increased to Buy at Zacks Investment Research” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this story on another website, it was illegally copied and republished in violation of US & international copyright & trademark laws. The legal version of this story can be accessed at https://sportsperspectives.com/2017/10/06/adaptimmune-therapeutics-plc-adap-rating-increased-to-buy-at-zacks-investment-research.html.
A number of hedge funds have recently modified their holdings of ADAP. Raymond James Financial Services Advisors Inc. acquired a new stake in Adaptimmune Therapeutics PLC in the 1st quarter valued at $120,000. KCG Holdings Inc. acquired a new stake in Adaptimmune Therapeutics PLC in the 1st quarter valued at $133,000. Monashee Investment Management LLC acquired a new stake in Adaptimmune Therapeutics PLC in the 1st quarter valued at $138,000. OxFORD Asset Management LLP acquired a new stake in Adaptimmune Therapeutics PLC in the 2nd quarter valued at $156,000. Finally, Paloma Partners Management Co acquired a new stake in Adaptimmune Therapeutics PLC in the 1st quarter valued at $165,000. Hedge funds and other institutional investors own 68.01% of the company’s stock.
Adaptimmune Therapeutics PLC Company Profile
Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.
Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.